| Biodistribution and dosimetry of a single dose of albumin-binding ligand [<sup>177</sup>Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Kramer, V., Fernández, R., Lehnert, W., Jiménez-Franco, L. D., Soza-Ried, C., Eppard, E., … Müller, C. (2021). Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. European Journal of Nuclear Medicine and Molecular Imaging, 48, 893-903. https://doi.org/10.1007/s00259-020-05022-3 |
| Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
Deberle, L. M., Benešová, M., Umbricht, C. A., Borgna, F., Büchler, M., Zhernosekov, K., … Müller, C. (2020). Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics, 10(4), 1678-1693. https://doi.org/10.7150/thno.40482 |
| Developments toward the implementation of <sup>44</sup>Sc production at a medical cyclotron
van der Meulen, N. P., Hasler, R., Talip, Z., Grundler, P. V., Favaretto, C., Umbricht, C. A., … Braccini, S. (2020). Developments toward the implementation of 44Sc production at a medical cyclotron. Molecules, 25(20), 4706 (16 pp.). https://doi.org/10.3390/molecules25204706 |
| Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of <sup>177</sup>Lu‐PSMA‐617 in LNCaP cells
Kranzbühler, B., Salemi, S., Umbricht, C. A., Deberle, L. M., Müller, C., Burger, I. A., … Eberli, D. (2019). Concentration‐dependent effects of dutasteride on prostate‐specific membrane antigen (PSMA) expression and uptake of 177Lu‐PSMA‐617 in LNCaP cells. Prostate, 79(12), 1477-1483. https://doi.org/10.1002/pros.23868 |
| Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute
Müller, C., De Prado Leal, M., Dominietto, M. D., Umbricht, C. A., Safai, S., Perrin, R. L., … Lomax, A. J. (2019). Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute. Pharmaceutics, 11(9), 450 (13 pp.). https://doi.org/10.3390/pharmaceutics11090450 |
| Preclinical investigations and first-in-human application of <sup>152</sup>Tb-PSMA-617 for PET/CT imaging of prostate cancer
Müller, C., Singh, A., Umbricht, C. A., Kulkarni, H. R., Johnston, K., Benešová, M., … Baum, R. P. (2019). Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Research, 9(1), 68 (10 pp.). https://doi.org/10.1186/s13550-019-0538-1 |
| Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
Müller, C., Umbricht, C. A., Gracheva, N., Tschan, V. J., Pellegrini, G., Bernhardt, P., … van der Meulen, N. P. (2019). Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1919-1930. https://doi.org/10.1007/s00259-019-04345-0 |
| First clinico-pathological evidence of a non PSMA-related uptake mechanism for <sup>68</sup>Ga-PSMA-11 in salivary glands
Rupp, N. J., Umbricht, C. A., Pizzuto, D. A., Lenggenhager, D., Töpfer, A., Müller, J., … Burger, I. A. (2019). First clinico-pathological evidence of a non PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands. Journal of Nuclear Medicine, 60(9), 1270-1276. https://doi.org/10.2967/jnumed.118.222307 |
| Alpha-PET for prostate cancer: preclinical investigation using <sup>149</sup>Tb-PSMA-617
Umbricht, C. A., Köster, U., Bernhardt, P., Gracheva, N., Johnston, K., Schibli, R., … Müller, C. (2019). Alpha-PET for prostate cancer: preclinical investigation using 149Tb-PSMA-617. Scientific Reports, 9, 17800 (10 pp.). https://doi.org/10.1038/s41598-019-54150-w |
| Albumin-binding PSMA ligands: optimization of the tissue distribution profile
Benešová, M., Umbricht, C. A., Schibli, R., & Müller, C. (2018). Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Molecular Pharmaceutics, 15(3), 934-946. https://doi.org/10.1021/acs.molpharmaceut.7b00877 |
| Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells
Kranzbühler, B., Salemi, S., Umbricht, C. A., Müller, C., Burger, I. A., Sulser, T., & Eberli, D. (2018). Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate, 78(10), 758-765. https://doi.org/10.1002/pros.23522 |
| Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application
Müller, C., Domnanich, K. A., Umbricht, C. A., & van der Meulen, N. P. (2018). Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. British Journal of Radiology, 91(1091), 20180074 (13 pp.). https://doi.org/10.1259/bjr.20180074 |
| Design and preclinical evaluation of an albumin-binding PSMA ligand for <sup>64</sup>Cu-based PET imaging
Umbricht, C. A., Benešová, M., Hasler, R., Schibli, R., van der Meulen, N. P., & Müller, C. (2018). Design and preclinical evaluation of an albumin-binding PSMA ligand for 64Cu-based PET imaging. Molecular Pharmaceutics, 15(12), 5556-5564. https://doi.org/10.1021/acs.molpharmaceut.8b00712 |
| Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy
Umbricht, C. A., Benešová, M., Schibli, R., & Müller, C. (2018). Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Molecular Pharmaceutics, 15(6), 2297-2306. https://doi.org/10.1021/acs.molpharmaceut.8b00152 |
| <sup>44</sup>Sc-PSMA-617 for radiotheragnostics in tandem with <sup>177</sup>Lu-PSMA-617—preclinical investigations in comparison with <sup>68</sup>Ga-PSMA-11 and <sup>68</sup>Ga-PSMA-617
Umbricht, C. A., Benešová, M., Schmid, R. M., Türler, A., Schibli, R., van der Meulen, N. P., & Müller, C. (2017). 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Research, 7(1), 9 (10 pp.). https://doi.org/10.1186/s13550-017-0257-4 |
| β-integrin de-phosphorylation by the Density-Enhanced Phosphatase DEP-1 attenuates EGFR signaling in <em>C. elegans</em>
Walser, M., Umbricht, C. A., Fröhli, E., Nanni, P., & Hajnal, A. (2017). β-integrin de-phosphorylation by the Density-Enhanced Phosphatase DEP-1 attenuates EGFR signaling in C. elegans. PLoS Genetics, 13(1), e1006592 (22 pp.). https://doi.org/10.1371/journal.pgen.1006592 |
